.png?width=1900&height=550&name=310W25-HERO-EMAIL-FINAL%20(1).png)
Safia Rizvi
CEO
Mark Burns
Director, Marketing Operations
Frank Nazzario
VP, Commercial
.jpg)
Archana Sondhi
Vice President Marketing and Commercial Strategy
Keith White
VP, Commercial
Marina Orlova
Executive Director, Commercial Strategy
Daniela van Eickels, MD, PhD, MPH
Senior Vice President, CMO Head of Medical Affairs
Taylor Salinardi, PhD
VP, Head of Global Medical Affairs role
Carolyn Reever, PhD
Global Head, Neuropsychiatry & Epilepsy Medical Affairs
Amy Everitt, PharmD, MS
Senior Director, Therapeutic Area Lead, Medical Affairs
Bree Kuntz
Senior Product Manager, HCP Marketing
Caroline Ojaimi
Executive Director, Medical Affairs Operations
Lynn Bass, PharmD
Medical Affairs Lead in Rare Disease Hematology and Cellular Therapy
Noelle Griffin
Global Head Nephrology & Transplant Medical Affairs
Michael Liberman
Senior Medical Director - Pipeline
Tina Rezakhani
Board Member
Helen Chang, RPh
Executive Director, Rare Disease Marketing
Wallace Mondesire, MD
Vice President
Katina Krambeck
Executive Director, Global Cardiovascular Pre-Launch Marketing & Innovation Readiness
Carlyn Martina-Mamber, PhD, MBA
Head of Medical Communications
Ann Westra
VP of Physician Engagement
5 pages · PDF
Free Event Guide
The complete launch readiness playbook for your team
Speakers, sessions, research insights, and pricing — everything you need to align your cross-functional team on attending.
✓ Instant download
✓ No spam
✓ Share with your team
18+
speakers
2
days
6
key themes
Pfizer BMS Takeda Vertex
8:00 AM
Networking
Registration and Networking Breakfast
9:00 AM
Opening
Opening Remarks: Setting the Stage for Successful Launches
Successful launches are built long before a product reaches the market. Opening this two-day event, this session will explore the strategies, planning, and cross-functional coordination required to prepare for today’s increasingly complex biotech and pharma launches. From clinical development and market access to medical affairs, commercialization, and operational readiness, attendees will gain insights into how leading organizations are aligning teams early, anticipating market challenges, and building launch plans designed to drive stronger execution and long-term success.
9:30 AM
Session
Inside the Launch Decision Room: Leadership Decisions That Shape a Product’s Path from Development to Launch
Explore how leadership teams structure organizations and build cross-functional launch teams early in development, aligning clinical, medical, commercial, and market access leaders around shared launch milestones.
- Understand how executives prioritize investments, allocate resources, and balance speed vs. certainty as assets move through Phase II/III and toward commercialization.
- Learn how organizations evaluate the true cost of clinical trials and long-term development, aligning capital planning, funding strategy, and launch investments to ensure sustainable execution.
- Hear how companies identify and partner with disease state foundations, advocacy organizations, and non-profits to support trial recruitment, patient education, and community trust while building early awareness ahead of launch.
- Examine how leadership teams engage KOLs, HCP networks, and patient communities to shape clinical development, evidence generation, and early scientific engagement strategies.
- Discover how executives break down silos and establish governance models that keep medical, commercial, and access teams aligned from development through launch execution.
Safia Rizvi
CEO · Cila Therapeutics
10:30 AM
Break
Networking Break
11:00 AM
Panel
From Strategy to Uptake: Building a Commercial Launch Engine That Drives Awareness, Adoption, and Growth
Hear from commercial leaders who have successfully launched products—or are preparing to launch now—as they share practical strategies, real-world lessons, and innovative approaches to building campaigns that drive awareness, adoption, and sustained growth.
- Translate brand strategy into a launch-ready commercial plan that aligns marketing, sales, market access, and analytics around shared launch goals and timelines.
- Build a scalable pre-launch awareness strategy that primes the market through segmentation, targeting, and omnichannel engagement.
- Design the field readiness model—training, messaging, tools, and KPIs—to ensure confident and consistent execution from day one.
- Leverage data, AI, and predictive analytics to identify priority audiences, personalize engagement, and optimize launch performance in real time.
- Develop integrated campaigns that connect digital, in-person, and peer-to-peer channels to accelerate early adoption.
- Align commercial messaging with Medical Affairs and Market Access to ensure consistent, compliant, and differentiated value communication.
- Establish launch dashboards and performance metrics that track awareness, engagement, uptake, and long-term growth beyond the initial launch window.
- Designing distribution strategies across specialty pharmacy, retail, hospital systems, and integrated delivery networks (IDNs) to ensure efficient product access and supply continuity at launch.
- Building early payer engagement strategies to understand evidence expectations and coverage requirements well before approval.
Frank Nazzario
VP, Commercial · Larimar Therapeutics
Archana Sondhi
VP Marketing & Commercial Strategy · IDEAYA Biosciences
Keith White
VP, Commercial · Disc Medicine
Marina Orlova
Executive Director, Commercial Strategy · Merck
Helen Chang RPh
Executive Director, Rare Disease Marketing · Shionogi
12:30 PM
Break
Networking Lunch
1:30 PM
Session
From Gap to Growth: Building Market Readiness Before Launch Through Disease Awareness, Partnerships, and Real-World Insight
How commercial and marketing teams can identify healthcare system gaps early and shape the environment, stakeholders, and messaging to ensure the market is truly ready for launch.
- Identifying healthcare system gaps, unmet needs, and disease recognition opportunities to shape the environment before product launch.
- Building early disease-state awareness campaigns and preparing the market through education, messaging, and competitive landscape analysis.
- Leveraging global and regional insights (including Japan and the U.S.) to tailor readiness strategies across healthcare systems, EMRs, and reimbursement environments.
- Partnering with professional societies, HCP congresses, advisory boards, and strategic collaborators to build credibility and engagement early.
- Understanding specialty vs. primary care dynamics and how they impact messaging, adoption, and market preparation.
- Using market research, patient advisory boards, and real-world evidence (RWE) to refine messaging, identify missing pieces, and demonstrate the “so what” impact.
- Activating partners and data sources (claims, RWE, and insights) to support early commercial, sales, and marketing readiness.
Katina Krambeck
Executive Director, Global Cardiovascular Pre-Launch Marketing & Innovation Readiness · Eli Lilly
2:15 PM
Session
Building the AI-Enabled Launch Engine: Embedding Intelligent Workflows Across Marketing, Sales, and Commercial Operations
A practical look at how pre-commercial teams can embed AI into marketing and commercial workflows to build scalable, compliant systems that power successful product launches.
- Learn how pre-commercial organizations can design scalable marketing and commercial systems while preparing for multiple launches, new indications, and reformulations.
- Explore how to embed AI into core workflows across promotional review, content lifecycle management, speaker programs, and campaign execution to improve speed, quality, and compliance.
- Understand how to connect marketing technologies, fulfillment systems, and CRM platforms to create a unified launch ecosystem and real-time performance visibility.
- Discover how to develop meaningful marketing KPIs, dashboards, and insights that guide decision-making and support launch readiness.
- Hear how cross-functional alignment across marketing, sales, IT, finance, and compliance enables governance, audit readiness, and scalable execution.
- Walk away with practical strategies for making AI a core operating model—not a side project—to drive measurable commercial launch impact.
Mark Burns
Director, Marketing Operations · Avidity Biosciences
2:45 PM
Break
Networking Break
3:15 PM
Session
Accelerating Launch Readiness: Building Scientific Narratives, Field Engagement, and Compliant Communications Under Compressed Timelines
As launch timelines shrink and stakeholder demands increase, Integrated Scientific Communications teams must rapidly align scientific narratives, publications, congress strategies, publications, and field readiness, to support successful launches in increasingly complex and fast-moving environments.
- Developing scalable communication frameworks that support both immediate launch execution and long-term stakeholder engagement.
- Aligning Medical Affairs, Scientific Communications, and Commercial teams around a unified launch strategy.
- Scaling Medical Communications capabilities through agile content development, outsourcing strategies, and cross-functional collaboration.
- Managing “last-mile” launch coordination, including label updates, medical field readiness, and rapid, compliant material deployment.
Carlyn Martina-Mamber, PhD, MBA
Head of Medical Communications · Lantheus
4:00 PM
Panel
Medical Affairs as the Strategic Launch Engine: Building the Team, Evidence, and Engagement Model for Launch Success
- Define how Medical Affairs leaders can shape launch strategy early by aligning evidence generation, insights, and cross-functional decision making across Commercial, Market Access, and Clinical teams.
- Build and scale a high-impact Medical Affairs launch team—defining roles, capabilities, resourcing models, and training needed to support pre- and post-approval success.
- Develop a modern KOL identification and engagement strategy that blends traditional thought leaders, rising experts, and digital opinion leaders to accelerate awareness and credibility.
- Design a congress strategy that maximizes scientific presence, drives meaningful engagements, and translates congress insights into actionable launch plans.
- Establish structured insight generation frameworks to capture field intelligence and turn it into strategic actions that influence launch readiness and lifecycle planning.
- Deep market understanding driven by medical insights - recognizing that insights are only valuable when they are translated into meaningful actions and strategic impact.
- Create a compliant, scalable scientific engagement model that strengthens relationships with healthcare professionals before, during, and after launch.
- Measure Medical Affairs launch impact using clear metrics and dashboards that demonstrate value to executive leadership and cross-functional partners.
Daniela van Eickels, MD, PhD, MPH
SVP, CMO Head of Medical Affairs · Kyowa Kirin
Taylor Salinardi, PhD
VP, Head of Global Medical Affairs role · SynOx Therapeutics
Carolyn Reever, PhD
Global Head, Neuropsychiatry & Epilepsy Medical Affairs · Biogen
Caroline Ojaimi
Executive Director, Medical Affairs Operations · BioNTech
Anna Murzhenko, PharmD
Medical Affairs Leader
Noelle Griffin
Global Head Nephrology & Transplant Medical Affairs · Biogen
Natalia Borinshteyn
Former VP, HCV Launch Team, Global and U.S. Medical Affairs, ABBVIE | Founder · Life Science Excellence
Wallace Mondesaire, MD
Vice President · Revolution Medicines
5:30 PM
Closing
End of Day One
8:00 AM
Networking
Networking Breakfast
8:45 AM
Opening
Opening Remarks and Day One Recap
9:00 AM
Keynote
The Power of Physician Engagement: Building Launch Momentum Through Strategic HCP Partnerships
Successful product launches are built long before commercialization begins — by creating meaningful physician partnerships that shape clinical strategy, scientific understanding, and real-world adoption. This session will explore how proactive physician engagement can align insights, evidence generation, and cross-functional execution to accelerate launch readiness and maximize patient impact.
- Transforming physician insights into launch strategy — Leveraging early and ongoing physician engagement to uncover unmet needs, refine clinical messaging, identify adoption barriers, and strengthen launch planning.
- Creating alignment across Commercial, Medical, and Clinical teams — Building cross-functional partnerships that connect scientific strategy, clinical development priorities, field engagement, and commercial execution to drive a unified launch approach.
- Moving beyond traditional KOL engagement — Developing deeper physician relationships through advisory boards, scientific exchange, and insight-driven engagement models that evolve throughout the product lifecycle.
- Strengthening market readiness through physician collaboration — Engaging physicians to support disease education, treatment pathway evolution, healthcare provider confidence, and broader adoption of new therapies.
- Using physician engagement as a competitive advantage — Establishing trusted relationships before launch to accelerate market understanding, improve execution, and ultimately enhance patient outcomes.
Ann Westra
VP of Physician Engagement| Priovant Therapeutics
10:00 AM
Session
Channel Strategy and Trade Readiness: Aligning Market Access, Distribution, and Commercial Execution for Launch
Learn how leading biotech and pharma companies design channel strategies, align payer expectations, and operationalize trade and distribution infrastructure to support a successful commercial launch
- Designing the right channel model (open distribution, specialty pharmacy, specialty distribution, or hybrid) based on product characteristics, patient population, and market access strategy.
- Leveraging pre-approval information exchange (PIE) to engage payers early and ensure channel design aligns with reimbursement and access expectations.
- Aligning medical, market access, and commercial teams around the channel strategy to support HCP adoption and patient adherence programs.
- Preparing trade and distribution operations including specialty distributor contracts, timelines, and inventory planning prior to approval.
- Building channel models that ensure the right balance of product availability, inventory management, and patient access at launch.
- Why trade strategy is often the “forgotten child” of launch planning and how organizations can elevate its importance across leadership teams
- Lessons learned from launches where channel design and distribution readiness significantly influenced commercial success
10:45 AM
Break
Networking Break
11:15 AM
Session
Build Patient-Powered Launches: Strategic Partnerships with Advocacy Groups, Nonprofits & Disease Communities
Explore how early, authentic partnerships with patients, advocacy groups, and disease-focused organizations can shape strategy, accelerate adoption, and drive meaningful impact across the entire product launch lifecycle.
- Build relationships with patient communities and advocacy organizations 12–24 months pre-launch to inform trial design, endpoints, and access strategy.
- Partner with advocacy groups and nonprofits to co-create education, support programs, and disease awareness initiatives that resonate with real patient needs.
- Align Medical Affairs, Commercial, and Market Access teams around patient insights to ensure consistent messaging and engagement strategies.
- Navigate compliance and regulatory considerations while maintaining authentic, value-driven patient. engagement across all touchpoints
- Leverage disease foundations and patient organizations to drive early market shaping, diagnosis pathways, and unmet need awareness.
- Establish long-term partnerships that extend beyond launch into adherence, support services, and real-world evidence generation
- Define and track meaningful KPIs to measure the impact of patient engagement on access, adoption, and patient outcomes
Tina Rezakhani, PharmD, MBA
Board Member | Amedea Pharma
12:00 PM
Networking
Networking Lunch
1:00 PM
Panel
From Insight to Impact: Building a Data-Driven Field Engagement Strategy that Drives Launch Success
Learn how leading pharma and biotech organizations design field engagement strategies that translate real-world insights into meaningful HCP interactions, stronger scientific exchange, and measurable long-term launch impact.
- Translate field insights from MSLs, KAMs, and field teams into actionable strategy to identify emerging scientific questions, unmet needs, and key stakeholder priorities ahead of launch.
- Identify and prioritize the right stakeholders including KOLs, community experts, digital opinion leaders, and emerging investigators who influence treatment adoption and patient pathways.
- Develop meaningful scientific engagement strategies that equip field teams with clear discussion. frameworks, scientific narratives, and compliant engagement objectives.
- Leverage engagement platforms, CRM systems, and insight management tools to capture field intelligence, identify trends, and enable stronger data-driven decision making.
- Connect field insights back to Medical, Commercial, Market Access, and Evidence Generation teams to strengthen cross-functional alignment and maximize launch impact.
Lynn Bass, PharmD
Medical Affairs Lead, Rare Disease Hematology · Mesoblast
Ana Bozas, PhD, CMPP
Medical Affairs & Medical Communications Leader
Sanaz Cardoza
Medical Affairs Strategy Leader
Michael Liberman
Senior Medical Director – Pipeline · Exelixis
2:00 PM
Session
Building Launch Alignment: How Medical Insights Shape Commercial Strategy, Messaging, and Execution
How early and continuous Medical Affairs leadership, KOL engagement, and cross-functional collaboration can translate scientific insight into aligned commercial messaging that accelerates launch adoption.
- Early Medical Affairs engagement during Phase III to ensure clinical insights and scientific narratives inform commercial launch strategy.
- Integrating MSL insights, conference intelligence, and market research to guide cross-functional decision making during pre-launch planning.
- Aligning Medical and Commercial teams around a shared understanding of disease state education, unmet need, and key data messaging at multiple levels throughout the company.
- Building collaboration models across Medical, Marketing, Field Sales, Field Medical, Market Access and Promotional Review teams to ensure alignment while respecting regulatory firewalls.
- Developing speaker bureau and peer-to-peer programs that translate unmet needs and data to address those gaps into credible HCP education and engagement.
- Executing a rapid and coordinated launch by ensuring Medical insights continuously inform messaging, field strategy, and post-launch activities
- Creating a culture that supports cross-functional collaboration through empowerment and recognition
Amy Everitt, PharmD, MS
Senior. Director, Therapeutic Area Lead · Praxis Precision Medicines
2:45 PM
Session
Exchange to Market Momentum: Designing HCP Engagement That Drives Launch Impact
Explore how early scientific engagement, cross-functional collaboration, and strategic peer-to-peer programs can transform HCP relationships into powerful drivers of launch readiness and sustained market adoption.
- Translating early Phase III scientific insights and unmet medical need research into messaging that resonates with HCPs at launch
- Navigating the medical-to-commercial transition while maintaining credibility, compliance, and scientific integrity
- Building cross-functional alignment between medical, marketing, and compliance teams to eliminate silos and avoid launch-stage surprises
- Engaging Key Opinion Leaders (KOLs) early to help shape educational content, disease awareness, and clinical narratives
- Designing peer-to-peer engagement strategies and speaker programs that accelerate trust, awareness, and clinical adoption
Bree Kuntz
Senior Product Manager, HCP Marketing · Verona Pharmaceuticals
3:30 PM
Closing
Conference Concludes
